Log In
BCIQ
Print this Print this
 

ALN-VSP, ASC-06

Also known as: formerly ALN-VSP01

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionRNA therapeutic targeting kinesin spindle protein (KSP) and VEGF genes
Molecular Target Vascular endothelial growth factor (VEGF) ; Kinesin spindle protein (KSP) (Eg5) (KIF11)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPhase I
Standard IndicationLiver cancer
Indication DetailsTreat advanced liver cancer; Treat hepatocellular carcinoma (HCC); Treat liver cancer
Regulatory Designation
PartnerAscletis Pharmaceuticals Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

$8.5M


 Deals Details
Get a free BioCentury trial today